FocalTherics Reports Q3 Revenue Up 26%, Narrows 2026 Guidance
FocalTherics reported third-quarter 2026 revenue of $9.8 million, up 26% year over year, and seven Focal One capital system sales. U.S. procedure volume rose 32% year over year and gross margin increased to 51.4% from 46.6%. The company narrowed its full-year revenue guidance to $50.0 million-$52.0 million from $50.0 million-$54.0 million and ended the quarter with $56.3 million in cash and cash equivalents.
FocalTherics™ (formerly EDAP TMS S.A.) reported total revenue of $9.8 million for the third quarter of 2026, representing a 26% increase compared to the same period in 2025. The company recorded seven Focal One® capital system sales during the quarter and saw a 32% increase in U.S. procedure volume year-over-year. Gross margin improved to 51.4% from 46.6% in the prior year period.
Additionally, the company narrowed its full-year 2026 revenue guidance to a range of $50.0 million to $52.0 million, down from its previous range of $50.0 million to $54.0 million. The company ended the quarter with $56.3 million in cash and cash equivalents.